
Clinical trials: Patient recruitment has begun
The ETH/PHRT-funded clinical study “RAPID 01”, which includes patients with acute myeloid leukemia (AML) who relapsed or are refractory to the initial standard of care therapy, is moving into the
Personalized Health and Related Technologies (PHRT) is a strategic focus area of the ETH Domain which encompasses six Swiss institutions: ETHZ, EPFL, PSI, Empa, Eawag and WSL. The main goal of PHRT is to drive the ongoing life science revolution that will ultimately transform medicine as it is today into ‘individualized medicine’. In essence, a person’s unique biological makeup will guide decisions on how to maintain and restore health. Thanks to its community of researchers and associated hospitals, PHRT is pushing the frontiers of knowledge on the mechanisms of diseases and opening the door to new treatments and technologies improving health and disease treatments.
The ETH/PHRT-funded clinical study “RAPID 01”, which includes patients with acute myeloid leukemia (AML) who relapsed or are refractory to the initial standard of care therapy, is moving into the
During the past few days the event «Personalized Health Technologies 2024” hosted by Nexus for which PHRT was the main sponsor took place. The event was held in the ETH
On June 25-26, 2024, PHRT organized an Education Retreat for the PhDs and postdocs working on PHRT projects with the goal of supporting scientific exchanges and strengthening the ties within